Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events

The aim of the CHARISMA (Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance) study was to evaluate dual antiplatelet therapy with clopidogrel plus low-dose aspirin in a broad population of patients at high risk for atherothrombotic events.

Bibliographische Detailangaben

Veröffentlicht in:	American journal of ophthalmology 2006-08, Vol.142 (2), p.366-366
Hauptverfasser:	Bhatt, D.L., Fox, K.A., Hacke, W., Berger, P.B., Black, H.R., Boden, W.E., Cacoub, P., Cohen, E.A., Creager, M.A., Easton, J.D., Flather, M.D., Haffner, S.M., Hamm, C.W., Hankey, G.J., Johnston, S.C., Mak, K.H., Mas, J.L., Montalescot, G., Pearson, T.A., Steg, P.G., Steinhubl, S.R., Weber, M.A., Brennan, D.M., Fabry-Ribaudo, L., Booth, J., Topol, E.J.
Format:	Artikel
Sprache:	eng
Schlagworte:	Aspirin Confidence intervals Drug therapy Heart attacks
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!